Aptahem’s CEO on upcoming milestones

Name: Aptahem’s CEO on upcoming milestones
Uploaded: 2022-11-24T08:48:54+01:00
Channel: BioStock
Description: Aptahem's CEO Mikael Lindstam visited BioStock's studio at Medicon Village in Lund to present the company and the ongoing rights issue

24 November, 2022

Aptahem gives update on operations and rights issue

Aptahem’s CEO on upcoming milestones

24 November, 2022

Aptahem has taken several steps forward in 2022. Recently, the biotech company passed a milestone with the start of the clinical phase I study with the sepsis candidate Apta-1. CEO Mikael Lindstam visited BioStock’s studio at Medicon Village in Lund to present the company and answer questions about the rights issue that is currently underway.

Watch the interview with Aptahem’s CEO Mikael Lindstam below.

The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.

Prenumerera på BioStocks nyhetsbrev

RELATED ARTICLESMORE FROM AUTHOR

Aptahem reports growing buzz around Apta-1

Aptahem comments on the publication in Cells

Aptahem’s CEO comments on Q2 and looks ahead

RELATED ARTICLES MORE FROM AUTHOR